Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

iRBD

  • Home
  •  
  • iRBD



  • Most Read
  • Latest Comments
  • First patients dosed in Phase 2 clinical trials to tackle Parkinson’s disease
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • First patients dosed in Phase 2 clinical trials to tackle Parkinson’s disease
    • News

    Pandemic poses opportunity to online learning platform OpenLearning
    Public
  • First patients dosed in Phase 2 clinical trials to tackle Parkinson’s disease
    • News

    Novatti partners with Ripple for global blockchain payments network
    Public
  • First patients dosed in Phase 2 clinical trials to tackle Parkinson’s disease
    • Opinion

    Is ASX: OOO the riskiest or smartest oil investment?
    Public
  • First patients dosed in Phase 2 clinical trials to tackle Parkinson’s disease
    AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • First patients dosed in Phase 2 clinical trials to tackle Parkinson’s disease
    First patients dosed in Phase 2 clinical trials to tackle Parkinson’s disease
    • News

  • Vitura receives first MDMA for its newly-minted psychedelics arm Cortexa
    Vitura receives first MDMA for its newly-minted psychedelics arm Cortexa
    • News

  • Clinical trial reveals promising outcomes for children with paediatric autoimmune neuropsychiatric disorders
    Clinical trial reveals promising outcomes for children with paediatric autoimmune neuropsychiatric disorders
    • News

  • Pharmaxis accelerates clinical drug developments with additional resources via sale of mannitol business to Arna Pharma
    Pharmaxis accelerates clinical drug developments with additional resources via sale of mannitol business to Arna Pharma
    • News

  • Direct marketing of biotags and global expansion mark BlueChiip’s cheery entry into FY24
    Direct marketing of biotags and global expansion mark BlueChiip’s cheery entry into FY24
    • News

  • First patients dosed in Phase 2 clinical trials to tackle Parkinson’s disease
    • News

    First patients dosed in Phase 2 clinical trials to tackle Parkinson’s disease

    Parkinson’s UK, in collaboration with Australian researchers, has taken a major step towards preventing the development of Parkinson’s disease with the first Australian patient in a Phase 2 clinical trial having been dosed with PXS-4708, a novel drug aimed at tackling  Parkinson’s before its onset, along with other neurodegenerative disorders. The multi-national trial was initiated

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.